GWS
VKTX icon

Glassman Wealth Services’s Viking Therapeutics VKTX Stock Holding History

Glassman Wealth Services’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-53
Closed – – 2047
2022
Q3 		$0 Hold
53
– – ﹤0.01% 2006
2022
Q2 		$0 Sell
53
-2
-4% -$5 ﹤0.01% 2018
2022
Q1 		$0 Buy
+55
New +$197 ﹤0.01% 1962

Other funds holding VKTX

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Glassman Wealth Services's VKTX Position: Q4 2022 in Review

Glassman Wealth Services sold out of Viking Therapeutics (VKTX) in Q4 2022, closing a stake of 53 shares.

Glassman Wealth Services first reported a position in VKTX in Q1 2022 and held it in 3 quarters. The position peaked at $0 in Q3 2022. 129 funds tracked by Wall St. Rank hold VKTX as of Q4 2022.

  • Glassman Wealth Services reported no remaining Viking Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Glassman Wealth Services sold 53 Viking Therapeutics shares in Q4 2022.
  • Glassman Wealth Services first reported a position in Viking Therapeutics in Q1 2022 and held it in 3 quarters.
  • Glassman Wealth Services's Viking Therapeutics position peaked at $0 in Q3 2022.
  • 129 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2022.

Based on Glassman Wealth Services's 13F filing for Q4 2022, filed 6 Feb 2023.